Brian Joseph Sheahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8594822/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular determinants of alphavirus neuropathogenesis in mice. Journal of General Virology, 2016, 97, 1283-1296.	1.3	13
2	Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model. Journal of General Virology, 2009, 90, 1848-1858.	1.3	51
3	The 5′ untranslated region as a pathogenicity determinant of Semliki Forest virus in mice. Virus Genes, 2008, 36, 313-321.	0.7	13
4	Therapeutic and prophylactic applications of alphavirus vectors. Expert Reviews in Molecular Medicine, 2008, 10, e33.	1.6	74
5	Semliki Forest virus vectors expressing the H and HN genes of measles and mumps viruses reduce immunity induced by the envelope protein genes of rubella virus. Vaccine, 2007, 25, 7481-7490.	1.7	2
6	Deletions in the hypervariable domain of the nsP3 gene attenuate Semliki Forest virus virulence. Journal of General Virology, 2006, 87, 937-947.	1.3	33
7	Alphaviruses and their Derived Vectors as Anti-Tumor Agents. Current Cancer Drug Targets, 2004, 4, 597-607.	0.8	15
8	Inhibition of matrix metalloproteinases ameliorates blood–brain barrier disruption and neuropathological lesions caused by avirulent Semliki Forest virus infection. Veterinary Immunology and Immunopathology, 2003, 94, 185-190.	0.5	12
9	Effect of intranasal administration of semliki forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Molecular Therapy, 2003, 8, 886-894.	3.7	34
10	Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine, 2001, 19, 1978-1988.	1.7	51
11	A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine, 2001, 19, 3877-3884.	1.7	20
12	Induction of apoptosis in BCLâ€2â€expressing rat prostate cancer cells using the Semliki Forest virus vector. International Journal of Cancer, 2001, 94, 572-578.	2.3	27
13	Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. Journal of General Virology, 2000, 81, 749-758.	1.3	56
14	The molecular pathogenesis of Semliki Forest virus: a model virus made useful?. Journal of General Virology, 1999, 80, 2287-2297.	1.3	78
15	Atypical Disease after Bordetella pertussis Respiratory Infection of Mice with Targeted Disruptions of Interferon-γ Receptor or Immunoglobulin μ Chain Genes. Journal of Experimental Medicine, 1997, 186, 1843-1851.	4.2	160
16	Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Molecular Biotechnology, 1996, 5, 33-38.	1.3	14
17	Semliki Forest Virus Expression System: Production of Conditionally Infectious Recombinant Particles. Nature Biotechnology, 1993, 11, 916-920.	9.4	242
18	Two mutations in the envelope glycoprotein E2 of semliki forest virus affecting the maturation and entry patterns of the virus alter pathogenicity for mice. Virology, 1991, 185, 741-748.	1.1	58

#	Article	IF	CITATIONS
19	Semliki Forest Virus Neurovirulence Mutants Have Altered Cytopathogenicity for Central Nervous System Cells. Infection and Immunity, 1982, 36, 333-341.	1.0	30